That is a really stupid post. If cytodyn was only in p2 GvHD trial and there was no HIV trials, pro 140 still has the potential to generate revenue well beyond the companies value. I actually think the reason we are not seeing a deal already is because HIV is huge and the stakes are high. BP is going to be very careful, so waiting for confirmation is worth it to them.